0000902664-25-004920.txt : 20251113 0000902664-25-004920.hdr.sgml : 20251113 20251113181536 ACCESSION NUMBER: 0000902664-25-004920 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20251113 DATE AS OF CHANGE: 20251113 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Oric Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001796280 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 471787157 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-91490 FILM NUMBER: 251480224 BUSINESS ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 388-5600 MAIL ADDRESS: STREET 1: 240 E. GRAND AVE. STREET 2: 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ALKEON CAPITAL MANAGEMENT LLC CENTRAL INDEX KEY: 0001230239 ORGANIZATION NAME: EIN: 134200093 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A BUSINESS ADDRESS: STREET 1: 350 MADISON AVENUE STREET 2: 20TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2127166576 MAIL ADDRESS: STREET 1: 350 MADISON AVENUE STREET 2: 20TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 SCHEDULE 13G/A 1 primary_doc.xml SCHEDULE 13G/A 0000902664-24-006454 0001230239 XXXXXXXX LIVE 3 Common Stock, par value $0.0001 per share 09/30/2025 0001796280 Oric Pharmaceuticals, Inc. 68622P109 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 Rule 13d-1(b) Alkeon Capital Management LLC DE 0.00 4504096.00 0.00 4504096.00 4504096.00 N 4.6 IA OO Panayotis D. Sparaggis X1 0.00 4504096.00 0.00 4504096.00 4504096.00 N 4.6 HC IN Oric Pharmaceuticals, Inc. 240 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080. This statement is filed by: (1) Alkeon Capital Management LLC ("Alkeon"), a Delaware limited liability company and the investment manager to certain funds (the "Alkeon Funds"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Oric Pharmaceuticals, Inc. (the "Company") directly held by the Alkeon Funds; and (2) Panayotis D. Sparaggis ("Mr. Sparaggis"), the Founder and Managing Director of Alkeon, with respect to the shares of Common Stock directly held by the Alkeon Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities and Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein. The address of the business office of each of the Reporting Persons is 350 Madison Avenue, 20th Floor, New York, NY 10017. The Investment Manager is a Delaware limited liability company. Mr. Sparaggis is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 97,122,987 shares of Common Stock outstanding as of August 5, 2025, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Securities and Exchange Commission on August 12, 2025. 4.6% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y N See Item 2. The Alkeon Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Alkeon Capital Management LLC /s/ Jennifer Shufro 11/13/2025 Panayotis D. Sparaggis /s/ Panayotis D. Sparaggis 11/13/2025